David Sachs Biography and Net Worth

CFO of ImmunityBio

Currently, David Sachs holds the position of Chief Financial Officer at ImmunityBio, Inc. He is also on the board of Keyssa, Inc., Mox Networks LLC, PacketFabric, Inc. and Chan Soon-Shiong Institute For Medicine.

He previously occupied the position of Principal at Nant Capital LLC, Chief Financial Officer of Integrity Healthcare LLC and Chief Financial Officer of NantKwest, Inc.

He received an undergraduate degree from the University of California, Los Angeles and an MBA from Anderson School of Management.

How old is David C. Sachs?: Mr. Sachs is currently 46 years old. There are 6 older executives and no younger executives at ImmunityBio. The oldest executive at ImmunityBio is Dr. Patrick Soon-Shiong F.A.C.S., FRCS, who is 71 years old. Learn More on David C. Sachs' age.
How do I contact David C. Sachs?: The corporate mailing address for Mr. Sachs and other ImmunityBio executives is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. ImmunityBio can also be reached via phone at (858) 633-0300 and via email at [email protected]. Learn More on David C. Sachs' contact information.
Has David C. Sachs been buying or selling shares of ImmunityBio?: David C. Sachs has not been actively trading shares of ImmunityBio during the past quarter. Learn More on David C. Sachs' trading history.
Who are ImmunityBio's active insiders?: ImmunityBio's insider roster includes Richard Adcock (CEO), Michael Blaszyk (Director), Cheryl Cohen (Director), David Sachs (CFO), and Barry Simon (Director). Learn More on ImmunityBio's active insiders.

David C. Sachs Insider Trading History at ImmunityBio

David C. Sachs Buying and Selling Activity at ImmunityBio

ImmunityBio Company Overview

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Today's Range

Now: $2.81

$2.76

$2.83

50 Day Range

MA: $4.54

$2.83

$6.17

2 Week Range

Now: $2.81

$2.76

$10.53

Volume

1,300,602 shs

Average Volume

5,040,906 shs

Market Capitalization

$1.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

This Crypto Is Set to Explode in December

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW